XTL Biopharmaceuticals (ADR) (XTLB)
Develops psychedelic therapies and active ingredients through Psyga Bio.
Something off on this page? Send us feedback.
Develops psychedelic and functional-mushroom intellectual property through Psyga Bio, pursuing clinical programs, licensing partnerships, and potential supply of active ingredients and formulations. The development-stage model has no established commercial revenue stream and depends on approvals, compliant manufacturing, and financing.
Develops and seeks to commercialize psychedelic and functional-mushroom intellectual property through majority-owned Psyga Bio, whose Israeli cleanroom facility is designed to cultivate, extract, formulate, and produce botanical and synthetic psilocybin, ibogaine, and related active ingredients. Research includes standardized microdosing formulations and early clinical programs across depression, PTSD, and anorexia.
Operations, the facility, and named research collaborations are concentrated in Israel, while the United States, Europe, and Asia are intended expansion regions. The model centers on acquiring technology, clinical development, partnerships, licensing, and potential supply of active ingredients and formulations.
No product has regulatory approval or an established commercial revenue stream. Progress depends on funding, trial execution, controlled-substance permissions, manufacturing certification and capacity, scientific personnel, clinical partnerships, and specialized treatment infrastructure.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $144.0K · Total debt $269.0K · Total assets $166.0K · Shareholders' equity −$254.0K
- Revenue
- $289.0K
- Operating income
- −$812.0K
- Net income
- −$255.0K
No dividends on record.
| Institutions6 holders · as of Mar 31, 2026 | 0.77% | 72.7K ADS | |
| Otherremainder | 99.23% | 9.39M ADS |
9.46M ADS (1 ADS = 100 ordinary shares) as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Noked Israel LtdInstitution | 0.53% | 49,722 ADS | 13Fas of Mar 31, 2026 |
Smartharvest Portfolios, LLCInstitution | 0.14% | 13,351 ADS | 13Fas of Mar 31, 2026 |
Rhumbline AdvisersInstitution | 0.06% | 5,987 ADS | 13Fas of Mar 31, 2026 |
Gamma Investing LLCInstitution | 0.04% | 3,388 ADS | 13Fas of Mar 31, 2026 |
Tower Research Capital LLC (TRC)Institution | 0.00% | 244 ADS | 13Fas of Mar 31, 2026 |
| See all 7 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Compass Pathways (ADR)
Closest psilocybin rival in treatment-resistant depression and PTSD.
- Definium Therapeutics
Advanced lysergide programs overlap in depression, anxiety, and PTSD.
- Atai Beckley
Rapid-acting neuroplastogens rival Psyga's psychedelic psychiatry platform.
- Helus Pharma
Deuterated psilocybin and DMT programs overlap in psychiatric trials.
- Psyence Biomedical
Nature-derived psilocybin and ibogaine supply overlap most directly.
- GH Research
5-MeO-DMT depression programs compete for psychedelic treatment adoption.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| XTL Biopharmaceuticals (ADR) | $2.58 | −3.01% | $2.5M | — | — | — | — |
| Compass Pathways (ADR) | $13.47 | +1.85% | $1.79B | — | — | — | — |
| Definium Therapeutics | $39.44 | +1.31% | $5.16B | — | — | — | — |
| Atai Beckley | $7.33 | −0.27% | $2.72B | — | — | 607.9 | +137.0% |
| Helus Pharma | $12.08 | +1.13% | $740.7M | — | — | — | — |
| Psyence Biomedical | $4.27 | −3.06% | $83.1K | — | — | — | — |
| GH Research | $28.08 | +2.63% | $1.92B | — | — | — | — |
| Median | — | — | 607.9 | +137.0% |